Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors
September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo
Updated on: October 12,2023
Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors
September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo
Updated on:October 12,2023
